
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Advances in the management of lower gastrointestinal bleeding</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Advances in the management of lower gastrointestinal bleeding</strong></summary>
            <div>
                <ul><li>- <b>Journal:</b> Aliment Pharmacol Ther. 2024;59:632–644.</li><li>- <b>DOI:</b> 10.1111/apt.17859</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the success rate of empirical embolization for tumor bleeding if active bleeding is present?</li><li>- What are the early and late rebleeding rates for diverticular bleeding even after endoscopic therapy?</li><li>- What is the diagnostic rate of nuclear medicine scintigraphy for acute LGIB?</li><li>- What is the attrition rate for patients scheduled for outpatient colonoscopy after an LGIB episode?</li><li>- The HALT-IT study showed that tranexamic acid was associated with an increased risk of what specific adverse event in GI bleeding?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Epidemiology & Aetiology</strong></summary>
            <div>
                <ul><li>- <b>Lower Gastrointestinal Bleeding (LGIB)</b> is defined as bleeding originating from the colon or anorectum (below the ligament of Treitz).</li><li>- Small bowel bleeding is now termed 'mid-gastrointestinal' bleeding.</li></ul>
                
        <details>
            <summary><strong>Incidence & Mortality</strong></summary>
            <div>
                <ul><li>- Incidence is increasing, currently <q><b>33–87 per 100,000</b></q> population.</li><li>- This rise is linked to an <u>ageing population</u> and increased use of <u>antithrombotics</u>.</li><li>- Overall mortality is <q><b>3.4%–8.8%</b></q>, but rises to <q><b>18%–20%</b></q> in already hospitalized patients.</li></ul>
                
        <details>
            <summary><strong>Mortality Details</strong></summary>
            <div>
                <ul><li>- Most deaths are related to underlying comorbidities.</li><li>- Death from severe bleeding itself accounts for <q><u><1%</u></q> of cases.</li><li>- Risk factors for mortality include advanced age, male sex, comorbidities (Charlson Comorbidity Index ≥2), long-term anticoagulant use, and hypovolemia.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Common Aetiologies</strong></summary>
            <div>
                <ul><li>- The most common cause of LGIB, especially in patients >60 years, is <b>diverticulosis</b>.</li><li>- In up to <q>25%</q> of cases, no specific aetiology is identified.</li></ul>
                
        <details>
            <summary><strong>Prevalence of Causes (See Table 1)</strong></summary>
            <div>
                <ul><li>- <b>Diverticulosis:</b> <q>25%–65%</q></li><li>- <b>Colonic ischaemia:</b> <q>5%–20%</q></li><li>- <b>Haemorrhoids:</b> <q>5%–20%</q></li><li>- <b>Colorectal polyps or cancer:</b> <q>2%–15%</q></li><li>- <b>Angiodysplasia:</b> <q>5%–10%</q></li><li>- <b>Post-polypectomy bleeding:</b> <q>2%–7%</q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Initial Assessment & Management</strong></summary>
            <div>
                <ul><li>- Initial management involves a focused history, physical exam, and lab evaluation performed concurrently with hemodynamic resuscitation.</li></ul>
                
        <details>
            <summary><strong>Initial Evaluation</strong></summary>
            <div>
                <ul><li>- <b>History:</b> Focus on symptoms (abdominal pain, weight loss), comorbidities (cardiovascular disease), and medications (<u>antithrombotics</u>, <u>NSAIDs</u>).</li><li>- <b>Physical Exam:</b> Assess vital signs (including orthostatic changes), and perform abdominal and digital rectal examinations.</li></ul>
                
        <details>
            <summary><strong>Upper GI Bleed (UGIB) Consideration</strong></summary>
            <div>
                <ul><li>- Haematochezia can occur with massive UGIB in up to <q><b>15%</b></q> of patients.</li><li>- Suspect UGIB in patients with hemodynamic instability, portal hypertension, or a history of peptic ulcer disease.</li><li>- An elevated BUN-to-creatinine ratio (<q>>30:1</q>) is highly suggestive of a UGIB source but lacks sensitivity.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk Stratification</strong></summary>
            <div>
                <ul><li>- Initial triage is based on hemodynamic stability using the <b>Shock Index (SI)</b>.</li><li>- <b>SI</b> = Heart Rate / Systolic Blood Pressure.</li></ul>
                
        <details>
            <summary><strong>Unstable Patients (SI > 1)</strong></summary>
            <div>
                <ul><li>- Patients with a shock index <q>>1</q> are considered unstable.</li><li>- These patients should proceed directly to <b>CT Angiography (CTA)</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Stable Patients (SI < 1)</strong></summary>
            <div>
                <ul><li>- Stable patients should be further risk-stratified using a dedicated LGIB risk score.</li></ul>
                
        <details>
            <summary><strong>Oakland Score</strong></summary>
            <div>
                <ul><li>- The <b>Oakland score</b> is the most discriminative tool for predicting <u>safe discharge</u>.</li><li>- A score of <q><b>≤8</b></q> correctly identifies patients for safe discharge in <q><b>95%</b></q> of cases.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Scores</strong></summary>
            <div>
                <ul><li>- The <b>Strate score</b> is best for predicting the need for hemostasis at endoscopy.</li><li>- Other scores include NOBLADS and BLEED.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Resuscitation & Transfusion</strong></summary>
            <div>
                <ul><li>- The primary goal is to preserve tissue perfusion and prevent organ damage.</li><li>- Secure two large-bore IV lines and administer crystalloid fluids.</li></ul>
                
        <details>
            <summary><strong>Blood Transfusion Strategy</strong></summary>
            <div>
                <ul><li>- Recommendations are largely extrapolated from UGIB literature.</li></ul>
                
        <details>
            <summary><strong>Restrictive Strategy (Stable Patients)</strong></summary>
            <div>
                <ul><li>- Transfuse packed red blood cells when hemoglobin is <q><b><7 g/dL</b></q>.</li><li>- The target hemoglobin level is <q><b>9 g/dL</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liberal Strategy (High-Risk Patients)</strong></summary>
            <div>
                <ul><li>- Consider for patients with underlying cardiovascular disease or hemodynamic instability.</li><li>- Transfuse when hemoglobin is <q><b><8 g/dL</b></q>, with a target of <q><b>10 g/dL</b></q> or greater.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Platelet Transfusion</strong></summary>
            <div>
                <ul><li>- Consider platelet transfusion only if the count is <q><b><50 × 10⁹/L</b></q> and urgent endoscopic hemostasis is required.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Antithrombotic Management</strong></summary>
            <div>
                <ul><li>- The primary goal is to balance the risk of worsening bleeding against the risk of thromboembolic events.</li><li>- Reversal agents are reserved for <u>life-threatening bleeding</u>.</li></ul>
                
        <details>
            <summary><strong>Life-Threatening Bleeding Definition</strong></summary>
            <div>
                <ul><li>- Bleeding resulting in hypovolemic shock or requiring pressors/surgery.</li><li>- Associated with a hemoglobin decrease of <q>>5 g/dL</q>.</li><li>- Requiring transfusion of <q>≥5 units</q> of packed red blood cells.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Antiplatelet Agents</strong></summary>
            <div>
                <ul><li>- <b>Platelet transfusion</b> is <u>not recommended</u> for patients on antiplatelets without thrombocytopenia due to lack of benefit and potential harm.</li></ul>
                
        <details>
            <summary><strong>Aspirin Management</strong></summary>
            <div>
                <ul><li>- <b>Primary Prevention:</b> <u>Stop</u> aspirin and reassess. USPSTF 2022 guidelines state risks outweigh benefits in patients <q>>60 years</q>.</li><li>- <b>Secondary Prevention:</b> <u>Do not stop</u> aspirin. If held, resume as soon as hemostasis is achieved.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dual Antiplatelet Therapy (DAPT)</strong></summary>
            <div>
                <ul><li>- <b>Aspirin:</b> Should not be held.</li><li>- <b>P2Y12 inhibitor:</b> Can be resumed within <q><b>5 days</b></q> to reduce thrombotic risk.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Anticoagulant Agents</strong></summary>
            <div>
                <ul><li>- For stable LGIB, the anticoagulant should be held on admission.</li></ul>
                
        <details>
            <summary><strong>Vitamin K Antagonist (VKA)</strong></summary>
            <div>
                <ul><li>- <b>Vitamin K</b> administration is not recommended due to its slow onset.</li><li>- <b>PCC</b> or <b>FFP</b> should be reserved for life-threatening bleeds only.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Direct Oral Anticoagulant (DOAC)</strong></summary>
            <div>
                <ul><li>- <b>Hold</b> the DOAC on admission for stable LGIB.</li><li>- Use <b>PCC</b> or a drug-specific reversal agent only for life-threatening bleeds if the drug was ingested in the last <q>24 hours</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Resumption of Anticoagulation</strong></summary>
            <div>
                <ul><li>- Restarting VKA and DOAC is suggested within <q><b>7 days</b></q> after bleeding cessation to decrease thromboembolic risk.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnostic Modalities</strong></summary>
            <div>
                <ul><li>- Diagnosis is challenging due to the intermittent nature of LGIB.</li><li>- Approximately <q>80%</q> of LGIB episodes, especially diverticular, stop spontaneously.</li></ul>
                
        <details>
            <summary><strong>Radiology: CT Angiography (CTA)</strong></summary>
            <div>
                <ul><li>- <b>Indication:</b> First-line test for <u>hemodynamically unstable</u> patients.</li><li>- <b>Performance:</b> Sensitivity <q><b>90%</b></q>, Specificity <q><b>92%</b></q>.</li><li>- Can detect bleeding rates as low as <q><b>0.3 mL/min</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Nuclear Medicine: Scintigraphy</strong></summary>
            <div>
                <ul><li>- Has a <u>limited and declining role</u> in LGIB diagnosis.</li><li>- <b>Limitations:</b> Long preparation time, low diagnostic rate (<q><50%</q>), and inaccurate localization of bleeding sites (<q>10%–33%</q> error rate).</li><li>- A study showed a diagnostic rate of only <q>38%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Endoscopy: Colonoscopy</strong></summary>
            <div>
                <ul><li>- Randomized trials and meta-analyses show <u>no clinical benefit</u> from early colonoscopy (<24h).</li><li>- <b>Recommendation:</b> Perform colonoscopy at the <u>next elective timeslot</u> or during hospital admission for stable patients.</li></ul>
                
        <details>
            <summary><strong>Considerations for Colonoscopy</strong></summary>
            <div>
                <ul><li>- Colonoscopy may be forgone if bleeding has stopped, the patient has known diverticulosis, and had a high-quality colonoscopy in the prior <q>12 months</q>.</li><li>- However, there is a high attrition rate for outpatient colonoscopy scheduling (up to <q>45%</q>).</li><li>- <b>Bowel Prep:</b> Split-dose or low-volume preps are acceptable. Unprepped colonoscopies are discouraged.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Modalities</strong></summary>
            <div>
                <ul><li>- A multidisciplinary approach is crucial.</li><li>- The majority of bleeding stops spontaneously, so many patients do not require acute intervention.</li></ul>
                
        <details>
            <summary><strong>Radiology: Transcatheter Embolization</strong></summary>
            <div>
                <ul><li>- <b>Indication:</b> First-line therapy for unstable LGIB with a bleeding source identified on CTA.</li><li>- <b>Timing:</b> Should be performed urgently after a positive CTA. Angiography within <q><b>90 minutes</b></q> of a positive CTA significantly increases therapeutic yield. ESGE recommends within <q>60 minutes</q>.</li></ul>
                
        <details>
            <summary><strong>Outcomes & Complications</strong></summary>
            <div>
                <ul><li>- <b>Clinical Success:</b> <q><b>63%–96%</b></q>.</li><li>- <b>Re-bleeding:</b> Up to <q>50%</q>, depending on aetiology (lower for diverticular, higher for angiodysplasia).</li><li>- <b>Major Complication:</b> Bowel ischemia in <q><b>1%–4%</b></q> of cases.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Endoscopic Therapy</strong></summary>
            <div>
                <ul><li>- Performed in stable patients with active bleeding or stigmata of recent hemorrhage (SRH).</li><li>- A distal attachment transparent cap can improve visualization and therapy delivery.</li></ul>
                
        <details>
            <summary><strong>Diverticular Bleeding</strong></summary>
            <div>
                <ul><li>- Endoscopic therapy reduces the risk of rebleeding compared to conservative treatment.</li><li>- However, rebleeding rates remain high: early rebleeding <q><b>17.4%</b></q>, late rebleeding <q><b>32.0%</b></q>.</li></ul>
                
        <details>
            <summary><strong>Treatment Options</strong></summary>
            <div>
                <ul><li>- <b>Through-the-scope (TTS) clips:</b> <u>Direct clipping</u> of the vessel is superior to indirect clipping.</li><li>- <b>Endoscopic Band Ligation (EBL):</b> May be the preferred method. Associated with less early rebleeding (<q>9%</q>) compared to TTS clips (<q>19%</q>) and thermal coagulation (<q>21%</q>).</li><li>- <b>Thermal Therapy:</b> Avoid at the base of the diverticulum due to perforation risk.</li><li>- <b>Injection Monotherapy:</b> Not recommended due to high rebleeding rates.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Vascular Lesions</strong></summary>
            <div>
                <ul><li>- For angiodysplasia and radiation proctitis, <b>Argon Plasma Coagulation (APC)</b> is safe and effective.</li><li>- A submucosal injection is recommended before thermal therapy in the thin-walled right colon to reduce perforation risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>New Hemostatic Tools</strong></summary>
            <div>
                <ul><li>- <b>Over-the-scope-clips (OTSC):</b> Show high success rates for diverticular, post-polypectomy, and anastomotic ulcer bleeding.</li><li>- <b>Topical Hemostatic Agents (e.g., Hemospray™):</b> Useful for diffuse bleeding. Achieves immediate hemostasis in <q><b>95%</b></q> of cases, with a 30-day rebleeding rate of <q>14.3%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Surgery</strong></summary>
            <div>
                <ul><li>- Reserved for patients who fail endoscopic or radiological therapy.</li><li>- Emergency surgery is rare, required in only <q><b>0.2%</b></q> of patients.</li><li>- <b>Segmental resection</b> is preferred over subtotal colectomy as it has lower morbidity and mortality.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pharmacological Therapy</strong></summary>
            <div>
                <ul><li>- Has a limited role, mainly for non-acute management of angiodysplasia.</li><li>- <b>Somatostatin analogues</b> and <b>thalidomide</b> have shown some promise but have limitations.</li><li>- <b>Tranexamic acid</b> is <u>not recommended</u>; the HALT-IT trial showed no benefit and an increased risk of <u>thromboembolic events</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Recurrence & Secondary Prophylaxis</strong></summary>
            <div>
                <ul><li>- Recurrent LGIB is a major challenge in management.</li></ul>
                
        <details>
            <summary><strong>Recurrent Bleeding</strong></summary>
            <div>
                <ul><li>- <b>Definition:</b> Bleeding after 24 hours of clinical stability or readmission within 1 week.</li><li>- <b>Rates:</b> In-hospital rebleeding is <q><b>4.4%</b></q>. 1-year recurrence is <q><b>13%–19%</b></q>, rising to <q><b>46%</b></q> at 5 years.</li><li>- Recurrence arises from the same site in only <q><b>37%</b></q> of patients.</li></ul>
                
        <details>
            <summary><strong>Risk Factors for Rebleeding</strong></summary>
            <div>
                <ul><li>- <b>Age ≥65 years</b> (HR: <q>1.7</q>)</li><li>- <b>Use of NSAIDs</b> (HR: <q>2.0</q>)</li><li>- <b>Non-aspirin antiplatelet drugs</b> (HR: <q>1.8</q>)</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Secondary Prophylaxis</strong></summary>
            <div>
                <ul><li>- Antiplatelet use is associated with recurrent LGIB (Monotherapy HR: <q>3.57</q>, DAPT HR: <q>5.3</q>).</li><li>- Use of <b>proton pump inhibitors (PPIs)</b> in patients on low-dose aspirin <u>did not</u> reduce the risk of LGIB.</li><li>- It is recommended to <u>discontinue non-aspirin NSAIDs</u> when possible.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Polypectomy Bleeding (PPB)</strong></summary>
            <div>
                <ul><li>- A common complication of polypectomy, accounting for <q><b>2%–7%</b></q> of all LGIB cases.</li></ul>
                
        <details>
            <summary><strong>Epidemiology & Risk Factors</strong></summary>
            <div>
                <ul><li>- <b>Incidence:</b> <q><b>0.2%–2.2%</b></q> overall, but can be as high as <q><b>6.5%</b></q> for polyps >2 cm.</li><li>- <b>Delayed PPB:</b> Can occur up to <q><b>14 days</b></q> after resection.</li></ul>
                
        <details>
            <summary><strong>Key Risk Factors (See Table 2)</strong></summary>
            <div>
                <ul><li>- <b>Polyp-related:</b> Size <q>>10 mm</q>, <u>right-sided</u> location, pedunculated morphology, hot snare polypectomy.</li><li>- <b>Patient-related:</b> Older age, cardiovascular disease, chronic kidney disease, use of anticoagulants or antiplatelets.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- The source of bleeding is known, so acute colonoscopy has a greater role than in other LGIB cases.</li><li>- However, bleeding stops spontaneously in <q><b>43%–55%</b></q> of patients.</li><li>- A selective approach to colonoscopy is beneficial in only <q>22%</q> of cases.</li></ul>
                
        <details>
            <summary><strong>Predictors of Active Bleeding at Colonoscopy</strong></summary>
            <div>
                <ul><li>- Left-sided polyp removal</li><li>- Use of electrocautery</li><li>- Use of anticoagulants</li><li>- Pedunculated polyp morphology</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prophylaxis</strong></summary>
            <div>
                <ul><li>- <b>Prophylactic clipping:</b> Can reduce delayed PPB risk for large (<q>>2 cm</q>) and proximal polyps.</li><li>- <b>Cold snare polypectomy:</b> Associated with a lower risk of delayed PPB compared to hot snare.</li><li>- <b>Self-assembling peptide (PuraStat®):</b> Shown to reduce delayed PPB risk after advanced endoscopic resection.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Future Directions & Conclusions</strong></summary>
            <div>
                <ul><li>- High-quality studies are needed to guide the management of LGIB.</li></ul>
                
        <details>
            <summary><strong>Research Gaps</strong></summary>
            <div>
                <ul><li>- Risk assessment scores like the <b>Oakland score</b> require further prospective validation.</li><li>- Comparative efficacy studies (e.g., embolization vs. endoscopic therapy) are needed.</li><li>- The role and outcomes of reversal agents for antithrombotics remain undefined.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Key Takeaways</strong></summary>
            <div>
                <ul><li>- <b>LGIB</b> is a common emergency with increasing incidence and worse outcomes than UGIB.</li><li>- <b>Diverticulosis</b> is the most common cause.</li><li>- <b>Initial Management:</b> Focus on hemodynamic stabilization and risk stratification (<u>Oakland score</u>).</li><li>- <b>Unstable Patients:</b> <u>CTA</u> is the preferred diagnostic and triage tool, followed by radiological embolization.</li><li>- <b>Stable Patients:</b> <u>Elective colonoscopy</u> is the standard of care.</li><li>- A <b>multidisciplinary approach</b> is essential for optimal outcomes.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
